Nastorazepide hemicalcium

Overview

Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [ 3 H]CCK-8 to the human CCK-2 receptor with a K i value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β , ephrin B1 , VEGF , and HIF-1alpha , reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer . Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > HIF/HIF Prolyl-Hydroxylase | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Cholecystokinin Receptor | Products > Signaling Pathways > Ephrin Receptor

Product Information

• Catalog No.: HY-14575
• CAS No.: 343326-69-2
• Molecular Formula: C29H36N4O5.1/2Ca
• Molecular Weight: 540.66
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source